Metabolism Drugs Market Stand Out As The Biggest Contributor In Healthcare

The global metabolism drugs market size was valued at US$ 5,765.3 million in 2017, and is expected to witness a robust CAGR of 6.3% over the forecast period (2018 – 2026).

Metabolic diseases is a wide category and there are several metabolism disorders caused due to clinically simple defects as well difficult to treat genetic disorders. For instance, obesity is most common type of metabolic disorder and is closely related to metabolic syndrome (a cluster of clinical conditions such as high blood sugar and triglycerides). According to the World Health Organization (WHO), over 650 million people aged 18 years and above were obese in 2016.

Another condition called lysosomal storage disease is a rare disorder, however, a significant number of people are affected with this disease. According to study published in Molecular Genetics and Metabolism Reports in December 2017, lysosomal storage disease has incidence rate of 1 in 4000 to 1 in 13,000 live births. Lysosomal storage disease consists of 60 genetic abnormalities with problematic enzyme function.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1955

Moreover, other rare diseases such as Hunter syndrome (Mucopolysaccaridosis type II (MPS II)), though rare, are life-threatening diseases with no curative treatment available, thus patients are made to rely on available therapies. According to the National Institute of Health 2018 report, Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Increasing incidence of hunter syndrome is expected to boost the metabolism disease drugs market. For instance, in 2014, around 970 patients were enrolled in Hunter Outcome Survey (HOC), which increased to 1195 patients in 2017.

Approvals to innovative therapies such as enzyme replacement therapy are expected to influence manufacturers to develop novel therapies in the market. This in turn, is expected to support the metabolism drugs market growth over the forecast period. The U.S. Food and Drug Administration (FDA) approved multiple drugs for gaucher disease. For instance, in 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by FDA for type 1 gaucher disease.

Moreover, research and development of novel therapies for treatment of rare metabolism diseases such as pompe, and others is expected to positively impact the metabolism drugs market growth. For instance, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of Pompe disease. Moreover, novel gene and RNAi therapies are also under research for treatment of these diseases.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1955

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.